Business Context and Reporting Period
Company: PAVmed Inc. (PAVM)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: PAVmed is a diversified commercial-stage life sciences company operating in medical devices, diagnostics, and digital health. It utilizes a shared services model with independently financed subsidiaries, including Lucid Diagnostics (EsoGuard test) and Veris Health (digital cancer care platform). The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $22 | $8 |
| Operating Expenses | $8,057 | $5,454 |
| Operating Loss | $(8,035) | $(5,446) |
| Net Income (Loss) Attributable to PAVmed | $(60) | $18,968 |
| Net Loss Attributable to Common Stockholders | $(6,988) | $17,695 |
| Net Loss Per Share (Basic & Diluted) | $(4.42) | $38.26 / $10.10 |
| Cash and Cash Equivalents (End of Period) | $6,460 | $2,700 |
| Net Cash Used in Operating Activities | $(2,620) | $(1,581) |
| Net Cash Provided by Financing Activities | $7,564 | $3,102 |
| Total Debt (Senior Secured Convertible Notes) | $14,900 (Fair Value) | $11,100 (Fair Value) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased to $22,000 from $8,000, driven by subscription revenue from the Veris Cancer Care Platform.
- Expense Increase: Total operating expenses rose by approximately $2.6 million ($8.1M vs $5.5M). General and Administrative (G&A) expenses increased by $2.0 million, primarily due to $2.4 million in financing-related professional fees, partially offset by lower stock-based compensation.
- Debt Restructuring: The company refinanced its September 2022 Senior Convertible Note. It issued a new "2026 Note" with a $15.0 million face value and a 15% interest rate, maturing in 2029. This resulted in a debt extinguishment loss of $3.4 million.
- Equity Transactions:
- Issued Series D Convertible Preferred Stock for $30 million gross proceeds; subsequently converted to 4.6 million common shares.
- Redeemed all outstanding Series C Preferred Stock.
- Completed a 1-for-30 reverse stock split effective January 2, 2026, regaining Nasdaq compliance.
- Investment Gains: Recognized an unrealized gain of $1.9 million on its equity method investment in Lucid Diagnostics, compared to a $21.0 million gain in the prior year period.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. Continued operations depend on controlling costs, increasing Veris revenues, and raising additional capital.
- Liquidity: As of March 31, 2026, the company held $6.5 million in cash. The 2026 Note includes financial covenants requiring available cash of at least $5.0 million (increasing to $8.0 million after July 1, 2026).
- Strategic Developments:
- Lucid Diagnostics: Submitted a request for reconsideration of Medicare coverage for EsoGuard; awarded a contract by the U.S. Department of Veterans Affairs.
- Veris Health: Launched commercial phase of partnership with Ohio State University Comprehensive Cancer Center.
- Medical Devices: Hired a Chief Business Officer for Medical Devices; licensed endoscopic imaging technology from Duke University.
- Risks: Key risks include the ability to obtain regulatory approvals, market acceptance of products, reliance on management fees from subsidiaries, and the need for future financing.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to meet the $5.0M/$8.0M cash covenants on the 2026 Note and its plan to secure additional funding.
- Debt Terms: Review the 15% interest rate and conversion terms ($450/share) of the new 2026 Note and the potential dilution from the Series D Warrants.
- Revenue Sustainability: Assess the scalability of the $22k revenue run-rate from Veris Health and the timeline for Medicare coverage of EsoGuard.
- Preferred Stock Obligations: Monitor the impact of Series B preferred dividends (8% annual) and the conversion mechanics of the Series D Preferred Stock.
- Stock-Based Compensation: Note the significant recent grant of restricted stock ($8.8M value) to directors and officers in April 2026, which will impact future expenses.